A Novel Therapeutic

We’re creating the first potential treatment for Demodex blepharitis

What is TP-03?

TP-03 is a topical ophthalmic formulation of lotilaner that, if approved, may offer treatment for millions of patients with Demodex blepharitis.1

Up to 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.1-3

TP-03 may change that.

The active ingredient in TP-03 is lotilaner, a well-characterized anti-parasitic agent that targets parasite-specific GABA-CI channels.1

Saturn-1 Phase 2b/3 Pivotal Trial

Presented by Elizabeth Yeu, MD, at ASCRS 2021 Annual Meeting.
References:

1. Tarsus Pharmaceuticals, Inc. announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis. Tarsus Pharmaceuticals, Inc. Press release. June 21, 2021. 2. Sadri E, Yeu E, Trattler W, Holdbrook M, Baba S. The prevalence of collarettes and Demodex blepharitis in ophthalmology and optometry practices. Presented at: ASCRS 2021. Abstract 75009. 3. Wilson FA, Stimpson JP, Wang Y. Inconsistencies exist in the national estimates of eye care services utilization in the United States. J Ophthalmol. doi:10.1155/2015/435606.

Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Opt in to be the first to receive the latest Tarsus news
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.